Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesThe FDA Reviews Safety of Stimulant Medication for ADHD
American Journal of Nursing, 10/01/09
Aschenbrenner DS – Research suggests that the use of stimulant drugs to treat ADHD is associated with a risk of sudden death in children. The FDA hasn't requested changes to stimulant drug labeling at this time but will continue to monitor studies on the subject. The FDA is urging health care providers to follow the current prescribing recommendations for stimulant drugs, including assessing for a history of cardiovascular disease and obtaining further tests if a risk or the presence of heart disease is suspected.
Related Articles
Electrocardiographic Screening in Children With Attention-Deficit Hyperactivity Disorder
The American Journal of Cardiology, 10/22/09
Relevance Score: 94%
Comorbidity in Adults With Attention-Deficit Hyperactivity Disorder
Canadian Journal of Psychiatry, 10/20/09
Relevance Score: 94%
Variability of Response Time as a Predictor of Methylphenidate Treatment Response in Korean Children with Attention Deficit Hyperactivity Disorder
Yonsei Medical Journal, 10/29/09
Relevance Score: 93%
Adolescent Girls With Attention-Deficit/Hyperactivity and Borderline Personality Disorders
Clinical Neuropharmacology, 10/12/09
Relevance Score: 93%
Dopaminergic Haplotype as a Predictor of Spatial Inattention in Children With Attention-Deficit/Hyperactivity Disorder
Archives of General Psychiatry, 10/09/09
Relevance Score: 93%
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Effects of Methylphenidate on Cerebral Glucose Metabolism in Patients With Impaired Consciousness After Acquired Brain Injury
Clinical Neuropharmacology, 12/05/09
Gabapentin Enacarbil in Restless Legs Syndrome: A Phase 2b, 2-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Clinical Neuropharmacology, 12/05/09
Inhibition of long-term potentiation by valproic acid through modulation of cyclic AMP
Epilepsia, 12/05/09
Sponsor
Article Search
Sponsor